Department of Advanced Biomedical Sciences, Federico II University, Via Pansini 5, 80131 Naples, Italy.
Department of Pharmacology and Pharmacotherapy, Semmelweis University, Nagyvárad tér 4, 1089 Budapest, Hungary.
Cardiovasc Res. 2021 Jan 21;117(2):367-385. doi: 10.1093/cvr/cvaa155.
Ischaemic heart disease (IHD) is a complex disorder and a leading cause of death and morbidity in both men and women. Sex, however, affects several aspects of IHD, including pathophysiology, incidence, clinical presentation, diagnosis as well as treatment and outcome. Several diseases or risk factors frequently associated with IHD can modify cellular signalling cascades, thus affecting ischaemia/reperfusion injury as well as responses to cardioprotective interventions. Importantly, the prevalence and impact of risk factors and several comorbidities differ between males and females, and their effects on IHD development and prognosis might differ according to sex. The cellular and molecular mechanisms underlying these differences are still poorly understood, and their identification might have important translational implications in the prediction or prevention of risk of IHD in men and women. Despite this, most experimental studies on IHD are still undertaken in animal models in the absence of risk factors and comorbidities, and assessment of potential sex-specific differences are largely missing. This ESC WG Position Paper will discuss: (i) the importance of sex as a biological variable in cardiovascular research, (ii) major biological mechanisms underlying sex-related differences relevant to IHD risk factors and comorbidities, (iii) prospects and pitfalls of preclinical models to investigate these associations, and finally (iv) will provide recommendations to guide future research. Although gender differences also affect IHD risk in the clinical setting, they will not be discussed in detail here.
缺血性心脏病(IHD)是一种复杂的疾病,也是男性和女性死亡和发病的主要原因。然而,性别会影响 IHD 的多个方面,包括病理生理学、发病率、临床表现、诊断以及治疗和预后。一些与 IHD 经常相关的疾病或风险因素可以改变细胞信号级联反应,从而影响缺血/再灌注损伤以及对心脏保护干预的反应。重要的是,风险因素和几种合并症在男性和女性中的患病率和影响不同,它们对 IHD 发展和预后的影响可能因性别而异。这些差异背后的细胞和分子机制仍知之甚少,它们的鉴定可能对男性和女性 IHD 风险的预测或预防具有重要的转化意义。尽管如此,大多数关于 IHD 的实验研究仍在缺乏风险因素和合并症的动物模型中进行,并且对潜在的性别特异性差异的评估在很大程度上被忽略了。这份 ESC WG 立场文件将讨论:(i)性别作为心血管研究中生物学变量的重要性,(ii)与 IHD 风险因素和合并症相关的性别差异的主要生物学机制,(iii)研究这些关联的临床前模型的前景和陷阱,最后(iv)将提供指导未来研究的建议。虽然性别差异也会影响临床环境中的 IHD 风险,但这里不会详细讨论。